Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nabriva Therapeutics
Biotech
The 2023 Biotech Graveyard
Nearly four times as many companies entered the biotech graveyard in 2023 compared to 2022.
Max Bayer
,
Gabrielle Masson
Oct 31, 2023 6:00am
Century, Elevation to cut assets, staff; Nabriva winds down
Jan 6, 2023 10:40am
Nabriva halts R&D, lays off 40% of staff in commercial refocus
Nov 11, 2022 7:35am
Nabriva eyes FDA filing after antibiotic clears pivotal test
May 21, 2018 9:28am
Roivant snags Chinese rights to Nabriva’s lefamulin in $95M deal
Mar 27, 2018 10:49am
Chutes & Ladders—J&J's longest-serving CFO Caruso to retire
Mar 23, 2018 9:00am
